{
    "id": 107,
    "premise": "none",
    "hypothesis": "This patient may develop resistance to Trastuzumab therapy.",
    "label": "entailment",
    "explanation": "overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "This patient may develop resistance to Trastuzumab therapy.",
        "history explanation": [
            "0 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "1 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "2 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "3 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "4 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "5 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "6 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "7 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "8 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "9 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab.",
            "10 iteration: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line.\nA portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy.\nPatient may benefit from treatment with Trastuzumab."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_0\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Overexpression :: \"entity \u21d2 bool\"\\n  HER2V777Lmutation :: \"entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  SoftAgarColonyFormationAssay :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  PortionOfTumours :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Beneficiary :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Overexpression x \u2227 HER2V777Lmutation y \u2227 Resulted e \u2227 TrastuzumabResistance z \u2227 SoftAgarColonyFormationAssay z \u2227 ColorectalCancerCellLine z \u2227 Agent e x \u2227 Patient e y \u2227 Patient e z\"\\n\\n(* Explanation 2: A portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PortionOfTumours x \u2227 Develop e \u2227 Resistance y \u2227 AntiHER2AntibodyTherapy z \u2227 Ultimately e \u2227 Agent e x \u2227 Patient e y \u2227 Patient e z\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. Patient x \u2227 Benefit y \u2227 Treatment z \u2227 Trastuzumab z \u2227 Agent y x \u2227 Beneficiary y z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy *)\\n shows \"\u2203x y z. Patient x \u2227 Develop y \u2227 Resistance z \u2227 Trastuzumab z \u2227 Agent y x \u2227 Patient z\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from treatment with Trastuzumab. *)\\n  then have \"\u2203x y z. Patient x \u2227 Benefit y \u2227 Treatment z \u2227 Trastuzumab z \u2227 Agent y x \u2227 Beneficiary y z\" <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy. *)\\n  then have \"\u2203x y z e. PortionOfTumours x \u2227 Develop e \u2227 Resistance y \u2227 AntiHER2AntibodyTherapy z \u2227 Ultimately e \u2227 Agent e x \u2227 Patient e y \u2227 Patient e z\" <ATP>\\n  (* We can combine the above two inferences to get the desired conclusion. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 10.928411483764648, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"bool\"\\n\\nType error in application: operator not of function type\\n\\nOperator:  Patient e :: bool\\nOperand:   y :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_107_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Overexpression :: \"entity \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  Assay :: \"entity \u21d2 bool\"\\n  ColonyFormation :: \"entity \u21d2 bool\"\\n  CancerCellLine :: \"entity \u21d2 bool\"\\n  InAssay :: \"entity \u21d2 entity \u21d2 bool\"\\n  ByAssay :: \"entity \u21d2 entity \u21d2 bool\"\\n  OfLine :: \"entity \u21d2 entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  Portion :: \"entity \u21d2 entity \u21d2 bool\"\\n  Develop :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntiHER2Therapy :: \"entity \u21d2 bool\"\\n  ToTherapy :: \"entity \u21d2 entity \u21d2 bool\"\\n  Ultimately :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Benefit :: \"entity \u21d2 bool\"\\n  FromTreatment :: \"entity \u21d2 entity \u21d2 bool\"\\n  WithTreatment :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v e. HER2Mutation x \u2227 V777L x \u2227 Overexpression y x \u2227 TrastuzumabResistance z \u2227 Assay w \u2227 ColonyFormation w \u2227 CancerCellLine v \u2227 InAssay z w \u2227 ByAssay z w \u2227 OfLine w v\"\\n\\n(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Tumors x \u2227 Portion y x \u2227 Develop z \u2227 Resistance z \u2227 AntiHER2Therapy e \u2227 ToTherapy z e \u2227 Ultimately y\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Trastuzumab z \u2227 Benefit e \u2227 FromTreatment e y \u2227 WithTreatment z y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 ToTherapy y z\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(Not(C), Not(A)), Implies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line)) *)\\n  (* We can infer that if the patient may not benefit from Trastuzumab, then the overexpression of a HER2 V777L mutation did not result in trastuzumab resistance. *)\\n  (* Since the patient may benefit from Trastuzumab, we can conclude that overexpression of a HER2 V777L mutation resulted in trastuzumab resistance. *)\\n  then have \"HER2Mutation x \u2227 V777L x \u2227 Overexpression x x \u2227 TrastuzumabResistance z \u2227 Assay w \u2227 ColonyFormation w \u2227 CancerCellLine v \u2227 InAssay z w \u2227 ByAssay z w \u2227 OfLine w v\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* Since we have the overexpression of a HER2 V777L mutation resulted in trastuzumab resistance, we can conclude that the patient may benefit from treatment with Trastuzumab. *)\\n  then obtain x y z e where \"Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 ToTherapy y z\" by auto\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_2\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Overexpression :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  Assay :: \"entity \u21d2 bool\"\\n  SoftAgar :: \"entity \u21d2 bool\"\\n  ColonyFormation :: \"entity \u21d2 bool\"\\n  CancerCellLine :: \"entity \u21d2 bool\"\\n  Colorectal :: \"entity \u21d2 bool\"\\n  By :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InAssay :: \"event \u21d2 entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  Portion :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntiHER2Therapy :: \"entity \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v e. HER2Mutation x \u2227 V777L x \u2227 Overexpression e \u2227 Agent e x \u2227 Resulted e1 \u2227 TrastuzumabResistance y \u2227 Assay z \u2227 SoftAgar z \u2227 ColonyFormation z \u2227 CancerCellLine w \u2227 Colorectal w \u2227 By e1 \u2227 Patient e1 y \u2227 InAssay e1 z \u2227 InAssay e1 w\"\\n\\n(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Tumors x \u2227 Portion y \u2227 Develop e \u2227 Agent e y \u2227 Patient e x \u2227 Resistance z \u2227 AntiHER2Therapy z \u2227 Ultimately e1 \u2227 To x z\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. Patient x \u2227 Trastuzumab z \u2227 Benefit e \u2227 Agent e x \u2227 From e z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n  shows \"\u2203x y z. Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from treatment with Trastuzumab. *)\\n  then have \"\u2203z. Trastuzumab z \u2227 Benefit e \u2227 Agent e x \u2227 From e z\" <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy. *)\\n  then have \"\u2203y z. Resistance y \u2227 AntiHER2Therapy z \u2227 Develop e1 \u2227 Agent e1 y \u2227 Patient e1 x \u2227 Ultimately e1 \u2227 To y z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Overexpression :: \"entity \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  SoftAgarColonyFormationAssay :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  By :: \"entity \u21d2 entity \u21d2 bool\"\\n  Of :: \"entity \u21d2 entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  Portion :: \"entity \u21d2 entity \u21d2 bool\"\\n  Develop :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Ultimately :: \"entity \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Benefit :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  May :: \"entity \u21d2 bool\"\\n  From :: \"entity \u21d2 entity \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v e. HER2Mutation x \u2227 V777L x \u2227 Overexpression y x \u2227 TrastuzumabResistance z \u2227 SoftAgarColonyFormationAssay w \u2227 ColorectalCancerCellLine v \u2227 Resulted e \u2227 Agent e y \u2227 Patient e z \u2227 By z w \u2227 Of w v\"\\n\\n(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Tumors x \u2227 Portion y x \u2227 Develop z \u2227 Resistance z \u2227 AntiHER2AntibodyTherapy e \u2227 Ultimately e \u2227 Patient e z \u2227 To z e\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Patient x \u2227 Benefit y \u2227 Treatment z \u2227 Trastuzumab z \u2227 May e \u2227 Patient e y \u2227 From y z \u2227 With y z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Resistance y \u2227 Trastuzumab z\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n  shows \"\u2203x y z e. Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\"\\nproof -\\n  (* From the premise, we can get the known information about the patient, resistance, and Trastuzumab. *)\\n  from asm have \"Patient x \u2227 Resistance y \u2227 Trastuzumab z\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can derive Implies(Not(C), Not(A)), Implies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line)) *)\\n  (* Since we have the premise that the patient has resistance and is treated with Trastuzumab, we can infer that the patient may develop resistance to Trastuzumab therapy. *)\\n  then have \"\u2203x y z e. Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 12.624805688858032, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Patient :: entity \\\\<Rightarrow> bool\\nOperand:   e :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_107_4\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Overexpression :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  Assay :: \"entity \u21d2 bool\"\\n  SoftAgar :: \"entity \u21d2 bool\"\\n  ColonyFormation :: \"entity \u21d2 bool\"\\n  CancerCellLine :: \"entity \u21d2 bool\"\\n  Colorectal :: \"entity \u21d2 bool\"\\n  By :: \"entity \u21d2 entity \u21d2 bool\"\\n  Of :: \"event \u21d2 entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  Portion :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  Resistance :: \"event \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Beneficiary :: \"event \u21d2 entity \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v e. HER2Mutation x \u2227 V777L x \u2227 Overexpression e \u2227 Agent e x \u2227 Resulted e y \u2227 TrastuzumabResistance y \u2227 Assay z \u2227 SoftAgar z \u2227 ColonyFormation z \u2227 CancerCellLine w \u2227 Colorectal w \u2227 By y z \u2227 Of e w\"\\n\\n(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Tumors x \u2227 Portion y \u2227 Develop z \u2227 Agent z y \u2227 Ultimately z \u2227 Resistance z \u2227 AntiHER2AntibodyTherapy z \u2227 To z y\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. Patient x \u2227 Trastuzumab z \u2227 Benefit e \u2227 Agent e x \u2227 Beneficiary e y \u2227 From e z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n shows \"\u2203x y z. Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\"\\nproof -\\n  (* From the premise, we know that the patient may benefit from treatment with Trastuzumab. *)\\n  from asm obtain a b c where \"Patient x \u2227 Trastuzumab c \u2227 Benefit a \u2227 Agent a x \u2227 Beneficiary a b \u2227 From a c\" by <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may develop resistance to Trastuzumab therapy. *)\\n  then have \"Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\" by <ATP>\\n  then show ?thesis by <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_5\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Overexpression :: \"entity \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  SoftAgarColonyFormationAssay :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  By :: \"entity \u21d2 entity \u21d2 bool\"\\n  Of :: \"entity \u21d2 entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  Portion :: \"entity \u21d2 entity \u21d2 bool\"\\n  Develop :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  With :: \"entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w v e. HER2Mutation x \u2227 V777L x \u2227 Overexpression y x \u2227 TrastuzumabResistance z \u2227 SoftAgarColonyFormationAssay w \u2227 ColorectalCancerCellLine v \u2227 Resulted e \u2227 Agent e y \u2227 Patient e z \u2227 By z w \u2227 Of w v\"\\n\\n(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Tumors x \u2227 Portion y x \u2227 Develop z \u2227 Resistance z \u2227 AntiHER2AntibodyTherapy y \u2227 Ultimately e \u2227 Patient e z \u2227 To z y\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Trastuzumab z \u2227 Benefit e \u2227 Agent e x \u2227 Patient e y \u2227 With y z\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n shows \"\u2203x y z e. Patient x \u2227 Resistance y \u2227 Trastuzumab z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 To y z\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from treatment with Trastuzumab. *)\\n  then have \"\u2203x y z e. Patient x \u2227 Treatment y \u2227 Trastuzumab z \u2227 Benefit e \u2227 Agent e x \u2227 Patient e y \u2227 With y z\" <ATP>\\n  (* There is a derived implication Implies(Not(C), Not(A)), Implies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line)) *)\\n  (* Since the patient may benefit from treatment with Trastuzumab, we can conclude that overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\n  then have \"\u2203x y z w v e. HER2Mutation x \u2227 V777L x \u2227 Overexpression y x \u2227 TrastuzumabResistance z \u2227 SoftAgarColonyFormationAssay w \u2227 ColorectalCancerCellLine v \u2227 Resulted e \u2227 Agent e y \u2227 Patient e z \u2227 By z w \u2227 Of w v\" <ATP>\\n  (* From the above, we can infer that the patient may develop resistance to Trastuzumab therapy. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_6\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  SoftAgarAssay :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  Overexpression :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  DevelopResistance :: \"event \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  AntiHER2Therapy :: \"entity \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  However :: \"event \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Beneficiary :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2Mutation x \u2227 TrastuzumabResistance y \u2227 SoftAgarAssay z \u2227 ColorectalCancerCellLine e \u2227 Overexpression e \u2227 Agent e x \u2227 Patient e z \u2227 Resulted e \u2227 Agent e x \u2227 Patient e y \u2227 By e y z\"\\n\\n(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. Tumors x \u2227 AntiHER2Therapy y \u2227 DevelopResistance e \u2227 Agent e x \u2227 Patient e y \u2227 Ultimately e \u2227 However e\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y. Patient x \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 Beneficiary e y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Trastuzumab y\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n shows \"\u2203x y e. Patient x \u2227 Trastuzumab y \u2227 DevelopResistance e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we know that the patient is receiving Trastuzumab. *)\\n  from asm have \"Patient x \u2227 Trastuzumab y\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from Trastuzumab treatment. *)\\n  then have \"Patient x \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 Beneficiary e y\" <ATP>\\n  (* There is a derived implication Implies(Not(C), Not(A)), Implies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line)) *)\\n  (* Since the patient is benefiting from Trastuzumab, we can conclude that the overexpression of HER2 V777L mutation resulted in trastuzumab resistance. *)\\n  then have \"HER2Mutation x \u2227 TrastuzumabResistance y \u2227 SoftAgarAssay z \u2227 ColorectalCancerCellLine e \u2227 Overexpression e \u2227 Agent e x \u2227 Patient e y \u2227 Resulted e \u2227 Agent e x \u2227 Patient e y \u2227 By e y z\" <ATP>\\n  (* From the above information, we can infer that the patient may develop resistance to Trastuzumab therapy. *)\\n  then have \"\u2203x y e. Patient x \u2227 Trastuzumab y \u2227 DevelopResistance e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_7\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Overexpression :: \"event \u21d2 entity \u21d2 bool\"\\n  ResultedIn :: \"event \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  ColonyFormationAssay :: \"entity \u21d2 bool\"\\n  SoftAgar :: \"entity \u21d2 bool\"\\n  CancerCellLine :: \"entity \u21d2 bool\"\\n  Tumors :: \"entity \u21d2 bool\"\\n  PortionOf :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2Mutation x \u2227 V777L x \u2227 Overexpression e x \u2227 ResultedIn e y \u2227 Resistance y \u2227 By e z \u2227 ColonyFormationAssay z \u2227 SoftAgar z \u2227 CancerCellLine z \u2227 PortionOf z\"\\n\\n(* Explanation 2: A portion of tumors, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. Tumors x \u2227 PortionOf x \u2227 Develop e x y \u2227 Ultimately e \u2227 Resistance y \u2227 To e y AntiHER2AntibodyTherapy y\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y. Patient x \u2227 Treatment y \u2227 Trastuzumab y \u2227 Benefit e x y\"\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n shows \"\u2203x y. Patient x \u2227 Resistance y \u2227 Develop e x y \u2227 To e y Trastuzumab\"\\nproof -\\n  (* From the premise, we know that the patient may benefit from treatment with Trastuzumab. *)\\n  from asm obtain a b where \"Patient x \u2227 Treatment a \u2227 Trastuzumab b \u2227 Benefit e x a\" by <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from treatment with Trastuzumab. *)\\n  then have \"Patient x \u2227 Treatment a \u2227 Trastuzumab b\" by <ATP>\\n  (* There is a derived implication Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* Since the patient may benefit from treatment with Trastuzumab, we can infer the overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\n  then have \"Patient x \u2227 Resistance y \u2227 Develop e x y \u2227 To e y Trastuzumab\" by <ATP>\\n  then show ?thesis by <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_8\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  SoftAgarAssay :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  Overexpression :: \"entity \u21d2 bool\"\\n  Resulted :: \"entity \u21d2 bool\"\\n  Agent :: \"entity \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 entity \u21d2 bool\"\\n  By :: \"entity \u21d2 entity \u21d2 bool\"\\n  Tumours :: \"entity \u21d2 bool\"\\n  AntiHER2Therapy :: \"entity \u21d2 bool\"\\n  DevelopResistance :: \"event \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Beneficiary :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2Mutation x \u2227 TrastuzumabResistance y \u2227 SoftAgarAssay z \u2227 ColorectalCancerCellLine e \u2227 Overexpression x \u2227 Resulted e \u2227 Agent e x \u2227 Patient e y \u2227 By e z\"\\n\\n(* Explanation 2: A portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Tumours x \u2227 AntiHER2Therapy y \u2227 DevelopResistance z \u2227 Agent z x \u2227 Patient z y \u2227 Ultimately z \u2227 To z y\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. Patient x \u2227 Trastuzumab y \u2227 Benefit z \u2227 Agent z x \u2227 Beneficiary z y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x \u2227 Trastuzumab y\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy *)\\n shows \"\u2203x y e. Patient x \u2227 Trastuzumab y \u2227 DevelopResistance e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we know that the patient is x and Trastuzumab is y. *)\\n  from asm have \"Patient x \u2227 Trastuzumab y\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from Trastuzumab treatment. *)\\n  then have \"Patient x \u2227 Trastuzumab y \u2227 Benefit z \u2227 Agent z x \u2227 Beneficiary z y\" for z <ATP>\\n  (* There is a logical relation Implies(B, C), Implies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy. *)\\n  then obtain a b c where \"Tumours a \u2227 AntiHER2Therapy b \u2227 DevelopResistance c \u2227 Agent c a \u2227 Patient c b \u2227 Ultimately c \u2227 To c b\" <ATP>\\n  (* We have the information about the patient, Trastuzumab, and the development of resistance. *)\\n  then have \"Patient b \u2227 Trastuzumab y \u2227 DevelopResistance c \u2227 Agent c b \u2227 Patient c y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 11.967917919158936, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Resistance :: entity \\\\<Rightarrow> bool\\nOperand:   y :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_107_9\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Overexpression :: \"entity \u21d2 bool\"\\n  HER2V777Lmutation :: \"entity \u21d2 bool\"\\n  Resulted :: \"event \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  SoftAgarColonyFormationAssay :: \"entity \u21d2 bool\"\\n  ColorectalCancerCellLine :: \"entity \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 entity \u21d2 bool\"\\n  PortionOfTumours :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntiHER2AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  However :: \"event \u21d2 bool\"\\n  Benefit :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  From :: \"entity \u21d2 entity \u21d2 bool\"\\n  May :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. Overexpression x \u2227 HER2V777Lmutation y \u2227 Resulted e \u2227 TrastuzumabResistance z \u2227 SoftAgarColonyFormationAssay z \u2227 ColorectalCancerCellLine z \u2227 By e z \u2227 Patient x \u2227 Cause e z\"\\n\\n(* Explanation 2: A portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e. PortionOfTumours x \u2227 Develop e \u2227 Resistance y \u2227 AntiHER2AntibodyTherapy z \u2227 Ultimately e \u2227 However e\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z. Patient x \u2227 Benefit y \u2227 Treatment z \u2227 Trastuzumab z \u2227 From x z \u2227 May y\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy *)\\n shows \"\u2203x y. Patient x \u2227 Develop y \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 May y\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from treatment with Trastuzumab. *)\\n  from explanation_1 have \"Patient x \u2227 Benefit y \u2227 Treatment z \u2227 Trastuzumab z \u2227 From x z \u2227 May y\" <ATP>\\n  (* We can derive the hypothesis from the above inference. *)\\n  then have \"\u2203x y. Patient x \u2227 Develop y \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 May y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_107_10\\nimports Main\\n\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2Mutation :: \"entity \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  Overexpression :: \"entity \u21d2 event \u21d2 bool\"\\n  ResultedIn :: \"event \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"entity \u21d2 bool\"\\n  By :: \"event \u21d2 entity \u21d2 bool\"\\n  ColonyFormationAssay :: \"entity \u21d2 bool\"\\n  SoftAgar :: \"entity \u21d2 bool\"\\n  CancerCellLine :: \"entity \u21d2 bool\"\\n  Tumours :: \"entity \u21d2 bool\"\\n  PortionOf :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Ultimately :: \"event \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  AntiHER2Therapy :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  From :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  With :: \"event \u21d2 entity \u21d2 entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2Mutation x \u2227 V777L x \u2227 Overexpression x e \u2227 ResultedIn e y \u2227 TrastuzumabResistance y \u2227 By e z \u2227 ColonyFormationAssay z \u2227 SoftAgar z \u2227 CancerCellLine z\"\\n\\n(* Explanation 2: A portion of tumours, however, ultimately develop resistance to anti-HER2 antibody therapy. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. Tumours x \u2227 PortionOf x \u2227 Develop e x y \u2227 Ultimately e \u2227 Resistance y \u2227 To e y AntiHER2Therapy\"\\n\\n(* Explanation 3: Patient may benefit from treatment with Trastuzumab. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y e. Patient x \u2227 Treatment y \u2227 Benefit e x y \u2227 From e x y \u2227 With e y Trastuzumab\"\\n\\n\\ntheorem hypothesis:\\n assumes asm: \"Patient x\"\\n  (* Hypothesis: This patient may develop resistance to Trastuzumab therapy. *)\\n shows \"\u2203x y e. Patient x \u2227 Resistance y \u2227 Develop e x y \u2227 To e y Trastuzumab\"\\nproof -\\n  (* From the premise, we know that the patient is x. *)\\n  from asm have \"Patient x\" <ATP>\\n  (* There is a logical relation Implies(A, C), Implies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab) *)\\n  (* We can infer that the patient may benefit from treatment with Trastuzumab. *)\\n  then have \"\u2203x y e. Patient x \u2227 Treatment y \u2227 Benefit e x y \u2227 From e x y \u2227 With e y Trastuzumab\" <ATP>\\n  (* There is a logical relation Implies(Not(C), Not(A)), Implies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line)) *)\\n  (* Since the patient may benefit from treatment with Trastuzumab, we can infer the overexpression of a HER2 V777L mutation resulted in trastuzumab resistance. *)\\n  then have \"\u2203x y z e. HER2Mutation x \u2227 V777L x \u2227 Overexpression x e \u2227 ResultedIn e y \u2227 TrastuzumabResistance y \u2227 By e z \u2227 ColonyFormationAssay z \u2227 SoftAgar z \u2227 CancerCellLine z\" <ATP>\\n  (* Combining the above two inferences, we can conclude that the patient may develop resistance to Trastuzumab therapy. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line\\nB: a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy\\nC: patient may benefit from treatment with Trastuzumab\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy)\\n--------\\nImplies(B, C)\\nImplies(a portion of tumors ultimately develop resistance to anti-HER2 antibody therapy, patient may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(A, C)\\nImplies(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line, patient may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient may benefit from treatment with Trastuzumab), Not(overexpression of a HER2 V777L mutation resulted in trastuzumab resistance by a soft-agar colony formation assay of a colorectal cancer cell line))\\n--------\\n'}"
        ]
    }
}